Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea.
Diabetes Metab J. 2019 Feb;43(1):49-58. doi: 10.4093/dmj.2018.0033. Epub 2018 Nov 2.
The prevalence of diabetes mellitus (DM) continues to increase, and the disease burden is the highest of any medical condition in Korea. However, large-scale clinical studies have not yet conducted to establish the basis for diabetes prevention in Korea.
The hospital-based Korean Diabetes Prevention Study (H-KDPS) is a prospective, multi-center, randomized, open-label controlled study conducted at university hospitals for the purpose of gathering data to help in efforts to prevent type 2 DM. Ten university hospitals are participating, and 744 subjects will be recruited. The subjects are randomly assigned to the standard care group, lifestyle modification group, or metformin group, and their clinical course will be observed for 36 months.
All intervention methodologies were developed, validated, and approved by Korean Diabetes Association (KDA) multi-disciplinary team members. The standard control group will engage in individual education based on the current KDA guidelines, and the lifestyle modification group will participate in a professionally guided healthcare intervention aiming for ≥5% weight loss. The metformin group will begin dosing at 250 mg/day, increasing to a maximum of 1,000 mg/day. The primary endpoint of this study is the cumulative incidence of DM during the 3 years after randomization.
The H-KDPS study is the first large-scale clinical study to establish evidence-based interventions for the prevention of type 2 DM in Koreans. The evidence gathered by this study will be useful for enhancing the health of Koreans and improving the stability of the Korean healthcare system (Trial registration: CRIS KCT0002260, NCT02981121).
糖尿病(DM)的患病率持续上升,其疾病负担是韩国所有医疗条件中最高的。然而,韩国尚未进行大规模的临床研究,为糖尿病预防奠定基础。
以医院为基础的韩国糖尿病预防研究(H-KDPS)是一项在大学医院进行的前瞻性、多中心、随机、开放性对照研究,旨在收集数据,帮助努力预防 2 型糖尿病。有 10 家大学医院参与,将招募 744 名受试者。这些受试者被随机分配到标准护理组、生活方式改变组或二甲双胍组,并观察他们 36 个月的临床病程。
所有干预方法均由韩国糖尿病协会(KDA)多学科团队成员制定、验证和批准。标准对照组将根据目前的 KDA 指南进行个体教育,生活方式改变组将参加专业指导的医疗干预,目标是减轻≥5%的体重。二甲双胍组将以 250mg/天的剂量开始给药,最大剂量增加到 1000mg/天。该研究的主要终点是随机分组后 3 年内糖尿病的累积发病率。
H-KDPS 研究是韩国首例为预防 2 型糖尿病而建立基于证据的干预措施的大规模临床研究。该研究收集的证据将有助于提高韩国人的健康水平,增强韩国医疗体系的稳定性(试验注册:CRIS KCT0002260,NCT02981121)。